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Summary 
The discovery of new antibiotics is one of the most urgent tasks facing scientists today. The 
escalating rate of resistant microbes creates a constant need for new or improved drugs. With 
the recent progress in genome sequencing a new world is opening up as researchers can explore 
bacterial antibiotic biosynthesis gene clusters that are normally silent under laboratory 
conditions. Waking up these silent gene clusters harbours the potential of novel drug discoveries 
to fight microbial infections, cancer or other major life-threatening conditions. In this work, 
genetic potential of Streptomyces bambergiensis, known producer of antibacterial antibiotic 
moenomycin, was investigated. Whole genome sequence of S. bambergiensis showed that it 
has, in addition to moenomycin cluster, 28 secondary metabolite biosynthetic gene clusters, 
including a giant polyketide synthase (PKS) gene cluster composed of 30 genes and spanning 
over 190 kb. The product of this gene cluster is unknown and likely not produced under 
laboratory conditions. First, moenomycin gene cluster was inactivated in S. bambergiensis by 
deletion in order to eliminate antibacterial background activity. Next, constitutive expression 
of the regulatory gene, a LuxR family transcriptional regulator, from the PKS gene cluster was 
accomplished, leading to the production of a compound with inhibitory activity against Bacillus 
subtilis. Preliminary analysis suggested that this may be a new compound that can be further 
studied as a potential antibiotic. 
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Abbreviations 
 
dH2O Distilled sterile water 
MoeD Moenomycin Deletion 
WT Wild Type 
C1R4 Overexpressed regulator number 4 in cluster 1 
C1R5 Overexpressed regulator number 5 in cluster 1 
C28R Overexpressed regulator in cluster 28 
SM Secondary Metabolite 
BuOH Butanol 
MeOH Methanol 
NaOH Sodium Hydroxide 
Kan Kanamycin 
Nal Nalidixic Acid 
Thio Thiostrepton 
Amp Ampicillin 
Cml Chloramphenicol 
Am Apramycin 
GUS β-Glucuronidase 
PCR Polymerase Chain Reaction 
OriT Origin or Transfer 
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1 Introduction 
1.1 Bacterial Secondary Metabolites 
The metabolites not directly essential for the development, growth and reproduction of an 
organism are categorized as secondary metabolites (SMs). These SMs have a wide variety of 
both chemical structures and biological activities. (Vining, 1992) 
Producers of SMs can be found among bacteria, fungi, plants and animals of both terrestrial 
and marine origin. There are many medical applications of SMs from micro organisms, 
including but not limited to antimicrobial, antiviral, tumor suppressing and immunosuppresant 
drugs. (Vaishnav & Demain, 2010)  
It is suggested that fitness and propagation of an organism in a particular environment is linked 
to its production of SMs. Most SMs are defense mechanisms of the organism, although SMs 
also have roles in mediation of the growth, reproduction and differentiation  as signaling 
molecules. (Vaishnav & Demain, 2010) The environment in which the organism evolves 
influenses the chemical structure and bioactivity of the SM, as survivability is highly increased 
in those organisms that evolve powerful defense mechanisms. (Vining, 1992) Many plants and 
bacteria form a symbiotic relationship, where the bacteria produces SMs which protect the plant 
host and the bacterial symbiont then gains nutrients from the host. (Challis & Hopwood, 2003) 
Whatever the exact roles of SMs are in nature, the main attraction of SMs for science and 
industry are their biological activities. One of the most important SMs for humans are the 
antibiotics.  
Alexander Fleming is a name most often associated with the advent of the antibiotic era. In 
1928, while investigating properties of staphylococci, he serendipitously discovered that some 
of his cultures had become contaminated by a fungus and that colonies surrounding the fungus,  
Penicillium rubens, had been eliminated, while  those further away seemed normal. This led to 
the discovery of penicillin and mass production of this antibiotic was established in 1945. 
(Fleming, 1929) The finding of the SM produced by this fungus became an inspiration for many 
novel antibiotic discoveries.  
The 1940s and early 1950s have been named the “golden era” of antibiotics as most groups of 
important antibacterial and antifungal antibiotics were discovered back then. These include 
tetracyclines, cephalosporins, aminoglycosides and macrolides. Between the 1970s and 1990s, 
there was a noticeable decline in antibiotic discovery. Although novel compounds were still 
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being discovered, they were mostly analogues of existing compounds or too toxic to be used as 
human medicines. (Bérdy, 2005) 
Still, the number of microbial SMs discovered since the 1940s has increased almost 
exponentially. By the end of 2002, the number of known bioactive SMs from microbes was 
over 22,000 (Figure 1). 
 
Figure 1: This figure shows the chronological distribution of discovered antibiotics from 1950 
- 2000. (Bérdy, 2005) 
However, the quantitative increase in  antibiotic discovery did not mean qualitative results in 
terms of drugs on the market, as the antibiotic drug approvals from microorganisms has been 
on a rapid decline, especially in the last decades. Irresponsible and incorrect use of antibiotics 
has caused many pathogens to evolve resistance to almost all existing drugs. (Zotchev S. B., 
Genomics-Based Insights into the Evolution of Secondary Metabolite Biosynthesis in 
Actinomycete Bacteria, 2014) From 1983 to 1987, 16 new antibiotics were approved by the 
FDA, compared to only 2 being approved between 2008 and 2011. (Hughes, 2011) This is 
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largely due to frequent re-discovery of existing compounds and high cost of screening, 
characterization and development. (Zotchev, Sekurova, & Katz, 2012) This can be seen in the 
following graph (Figure 2) from the IDSA. (Infectious Diseases Society of America, 2013) 
 
Figure 2: Chart showing the dramatic decrease in antibiotic drug approvals by the FDA. 
Now in the genomic era, when sequencing of whole genomes is possible, a world of 
opportunities opens up as a multitude of uncharacterized SM biosynthetic pathways are 
revealed. It has been found that in microbial genomes that encode for SM biosynthetic 
pathways, the genes are very often clustered together in groups. These clusters usually also 
contain regulators and transport systems. This allows software, such as, antiSMASH to easily 
identify novel biosynthetic pathways. (Zotchev, Sekurova, & Katz, 2012) This has the potential 
to revolutionize the discovery of novel bioactive substances in microorganisms. 
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1.2 OSMAC (One Strain-Many Compounds) 
Natural products are an important source of biologically active compounds and they continue 
to be of high interest to pharmaceutical companies. (Bertrand, et al., 2014) The search for novel 
natural products is one of the central subjects of industrial and academic research. OSMAC is 
an approach to focusing on the potential of each microorganism and elucidate the chemical 
diversity of natural products. (Bode, Bethe, Höfs, & Zeeck, 2002) Using the OSMAC approach, 
manipulation of the desired biosynthesis can be performed at different steps. The following 
figure (Figure 3) shows the possible ways to influence the biosynthesis of secondary 
metabolites. 
Manipulation of the biosynthetic pathway, using the OSMAC approach, can be performed at 
the translational, transcriptional and the metabolite level. The pathway towards the biosynthesis 
of SMs follows the usual metabolic pathway, that is, mRNA is transcribed from DNA and 
protein is translated from mRNA. (Bode, Bethe, Höfs, & Zeeck, 2002) The main focus of this 
project is the manipulation on the translational level.  
As can be seen in the following figure (Figure 4), each microorganism contains a multitude of 
different SM gene clusters. 
Figure 3: Possible ways to influence the biosynthesis of secondary metabolites. Using the 
OSMAC approach, manipulation of the biosynthetic pathway can occur at the transcriptional 
level, the translational level or the metabolite level. (Bode, Bethe, Höfs, & Zeeck, 2002) The 
main focus in this project is on the manipulation at the transcriptional level. 
5 
 
 
Figure 4: This phylogenetic tree shows genome size, isolation source and number of SM gene 
clusters of a 102 actinomycete genomes. The two bars plots are presented with species in the 
same order as the phylogenetic tree, representing genome size in thousands of genes on the left, 
coloured by habitat, and number of secondary metabolite gene clusters on the right, coloured 
by type of SM. (Doroghazi & Metcalf, 2013) 
This shows the high potential of each microorganism to biosynthesize various natural products 
and illustrates the importance of the OSMAC initiative. 
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1.3 Actinomycetes as Producers of Secondary Metabolites 
Actinomycetes are filamentous, gram-positive, aerobic, spore forming bacteria. They are 
known for their high G+C content, which can be over 70%. Actinomycetes derive their name 
from Greek, „aktis“ which means ray and „mykes“ which means fungus. This implies their 
resemblance to fungi as both actinomycetes and fungi form branched networks of hyphae. (Das, 
Lyla, & Khan, 2008) Actinomycetes are mostly terrestrial soil inhabitants, but are also found 
in various aquatic ecosystems.  
Actinomycetes are well-known and versatile producers of bioactive SMs,  including antibiotics, 
antitumor and immunosuppressive agents.  Major actinomycete producers of SMs include 
species from genera Streptomyces, Actinoplanes, Saccharopolyspora, Amycolatopsis and 
Micromonospora. These are all producers of what are now commercially important 
biomolecules. (Solanki, Khanna, & Lal, 2008) The best known SMs produced by actinomycetes 
are arguably the antibiotics. 
As can be seen in the following table (Table 1), microbes are important producers of bioactive 
compounds, with over 22,000 compounds discovered and of those, 17,000 have shown 
antibiotic activity. 
Table 1: Over 22,000 bioactive compounds have been discovered from microbes and about 
17,000 of those have shown antibiotic activity. (Bérdy, 2005) 
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The following table (Table 2) shows the distribution of bioactive SM producers for the various 
microbial species. 
Table 2: This table shows the distribution of bioactive SM producers for the various microbial 
species. Actinomycetes produce around 45% of the known microbial bioactive SMs and 75% of 
those actinomycetes were of the streptomyces species. (Bérdy, 2005) 
 
Actinomycetes are perhaps the most important producers of bioactive SMs. Around 45% of 
known microbial produced SMs are attributed to actinomycetes and 75% of those are of the 
Streptomyces species. 
As Streptomyces are such active producers of SMs, they seem ideal for further studies utilizing 
the latest technology in molecular genetics to discover and activate cryptic biosynthetic 
pathways. 
1.4 Secondary Metabolite Biosynthesis  
Each SM produced is the result of a complex biosynthetic pathway and thus has its cost for the 
producing cells in terms of precursors and energy. This can be taxing for the microorganism, 
and suggests that production of SMs is limited to situations where a survival benefit can be 
achieved. Biosynthesis of SMs may be limited by the availability of primary metabolites, which 
most often constitute building blocks for SMs. Morover, primary and secondary metabolisms 
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share common cofactors (e.g.NADPH) and energy sources (e.g. ATP), making these two 
processes tightly interlinked (Malik, 1980)  
For the synthesis of an SM, precursors from primary metabolism are utilized by the biosynthetic 
machinery to synthesize a molecular scaffold. This is followed by the modification of the 
scaffold by ”tailoring” enzymes, which add chemical groups to the scaffold, such as sugars, 
hydroxyl, methyl and amino groups. This results in a biologically active molecule and has the 
potential of self-toxicity for the organism that creates it. This is avoided by various resistance 
mechanisms implemented by the organism itself, and usually involves active efflux or 
modification of the molecule. (Zotchev S. B., Genomics-Based Insights into the Evolution of 
Secondary Metabolite Biosynthesis in Actinomycete Bacteria, 2014) 
For the assembly of the scaffold and its modification, the organism must biosynthesize a 
number of enzymes in a particular order and stoichiometry. This is achieved by the clustering 
of the biosynthetic genes in the organism’s genome and the regulation of gene expression by 
pathway-specific regulatory genes. (Zotchev S. B., Antibiotics Biosynthesis, 2008)  
Polyketides are a large class of secondary metabolites and includes the clinically relevant 
macrolide and tetracycline antibiotics. Polyketides show a remarkable functional and structural 
diversity. They are usually toxic for microorganisms and higher eukaryotes. (Jenke-Kodama, 
Sandmann, Muller, & Dittmann, 2005) Polyketides are synthesized by large enzymatic 
complexes called polyketide synthases (PKS). There is a large variety of different types of PKS 
enzymes with varying mechanistic complexities. The pathway to polyketide assembly is similar 
for most of them. PKSs are generally divided into three groups, the Type I, Type II and Type 
III. These are then further subdivided. (Zakeri & Lu, 2012) 
In the following figure (Figure 5), an example of type I PKS assembly of the antibiotic, 
erythromycin is shown.  
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Figure 5: This figure shows Type I PKS assembly of the erythromycin molecule. Three mega 
enzyme complexes (DEB-1, DEB-2, and DEB-3) produce erythromycin through interaction 
with acyl-CoA building blocks. The mega enzyme complexes constitute 7 individual domains 
(blue brackets). The scaffold molecule 6-DEB is assembled. Tailoring enzymes incorporate 
hydroxyl and sugar moieties to produce erythromycin. (Zakeri & Lu, 2012) 
Genome sequencing has revealed that each actinomycete bacterium has on average 20-30 gene 
clusters dedicated to the production of SMs and most of these are silent, that is, they are not 
expressed under laboratory conditions. (Doroghazi & Metcalf, 2013) The biosynthesis of an 
SM typically involves 10-30 genes, implying that this is a complicated process.  
Biosynthetic clusters in Streptomyces generally contain pathway-specific regulatory genes that 
control the onset of biosynthesis. These regulators also often control genes involved in 
antibiotic export and self-resistance. Onset of antibiotic production in Streptomyces starts in 
the transition phase, which is a temporary flattening of the growth curve before exponential 
phase continues. Expression of regulatory genes starts in the late lag/early exponential phase. 
(McArthur & Bibb, 2007) This means that the expression of regulatory genes begins earlier 
than the onset of the antibiotic production itself. Constitutive expression of regulatory genes 
may lead to premature antibiotic biosynthesis and overexpression of regulatory genes can result 
in marked increases in the level of antibiotic production. (Bibb & Hesketh, 2009)  
10 
 
In Streptomyces, two types of regulatory mechanisms have been investigated. The first one is 
the pathway-specific or pyramidal cascade of regulation. The best known of the pyramidal 
systems controls the biosynthesis of streptomycin, tylosin and cephamycic/clavulanic acid. 
(Martin & Liras, 2010) Small signalling molecules called γ-butarylactones, produced by 
Streptomyces species, bind to specific cytoplasmic receptor proteins, many of which act as 
repressors. The binding of the signalling molecule inhibits the receptor protein from binding to 
specific DNA targets and thus induces the expression of the target genes. Each receptor is highly 
specific for its cognate γ-butarylactone signal molecule. (Takano, 2006) Pyramidal cascades of 
regulation are pathway-specific and usually trigger the formation of SARP (Streptomyces 
antibiotics regulatory proteins) pathway family of regulatory proteins, most of which act as 
positive regulators of antibiotic biosynthesis. (Martin & Liras, 2010) 
The second regulatory mechanism is the global regulators, which are pleiotropic regulators, 
affecting several biosynthetic pathways. These are ususally two-component systems which 
respond to a variety of external stress signals. (Martin & Liras, 2010) Global regulatory genes 
are normally not found within SM gene clusters, but overexpression of global regulatory genes 
can result in the stimulation of SM production. (Aigle & Corre, 2012)  
The three types of pathway-specific regulatory proteins emphasized in this project are the 
positive regulators of the SARP family and the LAL (large ATP-binding regulators of the LuxR 
family) family and the negative regulators of the  TetR-like family. 
SARP regulators contain a winged helix-turn-helix motif towards their N-termini to bind to the 
promoter region of the target gene. They recognize heptameric repeats within the promoter 
regions of the genes that they regulate. They have been found associated with secondary 
metabolic gene clusters that encode ribosomally and non-ribosomally synthezised peptides, 
aromatic polyketides and type I and type II polyketides. SARP family of proteins has only been 
found within actinomycetes, and most within streptomycetes. (Bibb M. J., 2005) Most 
characterized SARPs act as specific regulators at the bottom of regulatory cascades and turn on 
the expression of the biosynthetic genes in the given cluster. (Aigle & Corre, 2012) 
LuxR family of transcriptional regulators are well know as key players in Quorum Sensing, 
coordinating the expression of a variety of genes, including  genes encoding for virulence 
factors, biofilm formation and antibiotics biosynthesis. (Chen & Xie, 2011) LuxR family of 
regulators have a C-terminal helix-turn-helix motif. In actinomycetes, the best known members 
of the LuxR family are the LAL family. Unlike the SARP regulators, that have only been 
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identified in actinomycetes, the LAL regulators were first identified in protebacteria. (Schrijver 
& Mot, 1999) Several regulators of the LAL family have been identified in antibiotic and other 
SM gene clusters from actinomycetes. They are considered pathway-specific regulators. 
(Guerra, et al., 2012) Although knowledge regarding LAL family of regulators involved in 
biosynthesis of SMs in Streptomyces is limited, Huang et al reported enhanced antibiotic 
(rapamycin) production in Streptomyces hygroscopius, by over-expression of a pathway 
specific regulator of the LAL family. (Huang, et al., 2011) Also, Laureti et al showed that the 
constitutive overexpression of a regulator gene, encoding a protein that is similar to LAL family 
proteins, of a gene cluster in Streptomyces ambofaciens resulted in the production of a novel 
macrolide with antitumor activity. (Laureti, et al., 2011) (Zotchev, Sekurova, & Katz, 2012) 
TetR-like family of repressors have a helix-turn-helix motif. TetR regulator proteins are 
involved in the transcriptional control of multidrug efflux pumps, pathways for the biosynthesis 
of antibiotics, response to osmotic stress and toxic chemicals, control of catabolic pathways, 
differentiation processess, and pathogenicity. Usually TetR binds to target operator and 
represses tetA transcription and is released in the presence of tetracycline, but the pathway can 
be more complex. (Ramos, et al., 2005) γ-butarylactone receptor proteins are TetR-like 
repressors. Gottelt et al showed that the deletion of ScbR, which is a γ-butarylactone receptor 
protein of S. coelicolor that binds to specific DNA sequences in front of its target genes, 
repressing their transcription, resulted in the expression of a silent gene cluster, which yielded 
a previously undetected compound with antibacterial activity.  (Gottelt, Kol, Gomez-Escribano, 
Bibb, & Takano, 2010) 
1.5 Genome Based Mining for Novel Secondary Metabolites 
Now in the age of genome sequencing, one can obtain almost whole genomes of organisms in 
a matter of weeks. This opens up incredible oportunities, but also requires a considerable effort 
in data handling. (Zotchev, Sekurova, & Katz, 2012) The development of the software 
antiSMASH has helped in this regard. AntiSMASH is able to accurately identify gene clusters 
encoding SMs of nearly all known chemical classes. (Blin, et al., 2013) AntiSMASH provides 
links to the online software BLAST for the identification of proteins encoded by genes in a 
given cluster. Using this, an annotation of the gene clusters and prediction of their products can 
be achieved.  
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1.6 Project Background 
Streptomyces are known producers of a wide variety of biologically active SMs. Recent 
sequencing of several Streptomyces genomes revealed many unknown gene clusters for 
biosynthesis of potentially novel biologically active SMs, which have not been detected in a 
conventional screening. Most likely these gene clusters are not expressed under laboratory 
conditions, and need to be activated to achieve production of novel compounds. However, it is 
not fesible to activate all gene clusters present in Streptomyces bacterium, which is on average 
between 20-30 per genome. (Doroghazi & Metcalf, 2013) A careful bioinformatic analysis of 
the gene clusters can be helpful in selection of the most interesting ones to be targeted for 
activation.  
Almost all SM gene clusters contain regulatory genes. These genes control the expression of 
the biosynthetic genes. These regulator genes can be manipulated in order to coax the organism 
into producing more of the SMs. Inactivation of a repressor gene or overexpression of a positive 
regulator are examples of methods currently being used to manipulate organisms into increasing 
their production of SMs. S. bamgergiensis ATCC 13879 is a producer of the antibiotic 
moenomycin (flavomycin) complex (Zotchev, Rozenfeld, & Zhdanov, Transformation of 
streptomyces bambergiensis S712 protoplasts with plasmid DNA, 1988). This antibiotic is a 
phosphoglycolipid antibiotic inhibiting peptidoglycan formation in Gram-positive bacteria, and 
no other SMs have so far been reported from S. bambergiensis. (Ostash & Walker, 2010) Using 
a recently obtained complete genome sequence of S. bambergiensis, 29 SM biosynthesis gene 
clusters have been identified in this bacterium using the online software antiSMASH.   
1.7 Project Goals 
A flowchart of the project can be seen on the next page. 
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Through bioinformatics, identify gene 
clusters potentially governing 
biosynthesis of SMs, using AntiSMASH 
2.0
Remove background by deleting 
moenomycin gene cluster in 
Streptomyces bambergiensis
Identify and clone pathway-specific 
regulators
Investigate recombinant strains for 
production of new compounds, using 
bioassays, UV scans and HPLC
Mining, analysis and targeted activation of 
secondary metabolite gene clusters in 
Streptomyces bambergiensis
Annotation and analysis of gene clusters, 
using BLAST, Excel and Clone Manager
Overexpress regulatory genes in 
Streptomyces bambergiensis 
moenomycin deletion mutant
 
 
The major goal of the project was to attempt a discovery of novel SM through genome mining 
of S. bambergiensis.  
The sub-goals were: 
- To identify, using bioinformatics, biosynthetic gene clusters for potentially novel SMs 
- To inactivate moenomycin biosynthesis in S. bambergiensis 
- To activate two selected target gene clusters via overexpression of their pathway-
specific regulators 
- To test biological activity of the activated recombinant strains   
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2 Materials 
2.1 Bacterial Strains and Vectors Used in This Work 
Bacterial strain or vector Relevant properties 
Source or 
reference   
S. bambergiensis      
 
S. bambergiensis Wild 
Type 
Wild type, moenomycin producing (Zotchev, Soldatova, 
Orekhov, & Schrempf, 
1992)  
 
S. bambergiensis MoeD S. bambergiensis Moenomycin 
deletion mutant This work    
 
S. bambergiensis MoeD 
C1R4 
S. bambergiensis Moenomycin 
deletion mutant with overexpressed 
regulator 4 in cluster 1 This work    
 
S. bambergiensis MoeD 
C1R5 
S. bambergiensis Moenomycin 
deletion mutant with overexpressed 
regulator 5 in cluster 1 This work    
 
S. bambergiensis MoeD 
C28R 
S. bambergiensis Moenomycin 
deletion mutant with overexpressed 
regulator in cluster 28 This work    
E. Coli      
 XL1-blue Strain used for transformation Stratagene   
 
ET12567 Strain used for transformation of 
non-methylated DNA 
(Flett, Mersinias, & 
Smith, 1997) 
Vectors      
 
pSOK806 Vector used for introduction of 
regulatory genes (Sekurova, et al., 2004)   
 
pSOK808 Vector used for deletion of 
moenomycin gene cluster (Sekurova, et al., 2004)   
 
pSOK806 C1R4 Vector containing regulatory gene 4 
in cluster 1 This work    
 
pSOK806 C1R5 Vector containing regulatory gene 5 
in cluster 1 This work    
 
pSOK806 C28R Vector containing regulatory gene in 
cluster 28 This work    
 
pSOK808 MoeD Vector contining A and B parts 
flanking the moenomycin gene 
cluster This work    
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2.2 Media 
2 X YT    
Difco Bacto Tryptone 16 g   
Difco Bacto Yeast Extract 10 g   
NaCl 5 g   
dH2O 1000 ml   
    
Autoclaved at 120°C for 20 minutes. Stored at room 
temperature. 
    
LB    
Difco Bacto Tryptone 10 g   
Difco Bacto Yeast Extract 5 g   
NaCl 5 g   
dH2O 1000 ml   
    
Autoclaved at 120°C for 20 minutes. Stored at room 
temperature. 
    
LA    
Difco Bacto Tryptone 10 g   
Difco Bacto Yeast Extract 5 g   
NaCl 5 g   
Agar 15 g   
dH2O 1000 ml   
    
Autoclaved at 120°C for 20 minutes. Stored at room 
temperature. 
    
ISP4    
DifcoTM ISP Medium 4 37 g   
dH2O 1000 ml   
    
Autoclaved at 120°C for 20 minutes. Plates stored at 4 °C. 
    
ISP4 + MgCl2    
DifcoTM ISP Medium 4 37 g   
1 M MgCl2 Stock Solution 10 ml   
dH2O 1000 ml   
    
Autoclaved at 120°C for 20 minutes. Plates stored at 4 °C. 
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TSS (Transformation 
Storage Solution)    
LB Broth 42.5 ml   
PEG6000 5 g   
1 M MgCl2 Stock Solution 2.5 ml   
DMSO 2.5 ml   
    
PH adjusted to 6.5. Autoclaved at 120°C for 20 minutes, 
DMSO added after autoclavation. 
    
TSB Medium    
Tryptone Soya Broth 30 g   
dH2O 1000 ml   
    
Autoclaved at 120°C for 20 minutes. Stored at room 
temperature. 
    
PM4-1 Medium    
Glucose 150 g   
Soy Meal 15 g   
Corn Steep Solids (Sigma) 5 g   
CaCO3 2 g   
TMS 1 Stock Solution 6 ml   
dH2O 1000 ml   
 
Glucose solution (150g/L) was prepared and sterilized. 5 g of Corn Steep Solids were dissolved 
in 890 mL of distilled water. Corn Steep Solids were poured into 3 flasks (297 mL in each). 
While stirring, 5 g of Soy Meal and 0.7 g of CaCO3 were added to each flask. The flasks were 
then stirred for 5 minutes and autoclaved at 120°C for 20 minutes. After sterilization, under a 
sterile hood, 100 ml of sterile 150 g/L glucose solution and 2 mL of TMS1 stock solution was 
added to each flask.  
Lysis Buffer   
Tris HCL - pH 8.0 1 ml  
EDTA - pH 8.0 1 ml  
Triton Stock Solution 6.25 ml  
dH2O 41.75 ml  
   
5x Isothermal Mix 
(Gibson Mix)   
5x Isothermal Buffer 160 μl  
10u-1 μl T5 Exonuclease 0.32 μl  
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2u-1 μl T5 Phusion DNA 
Polymerase 10 μl  
40u-1 μl Taq DNA Ligase 80 μl  
dH2O  
up to 600 
μl  
   
Stored in 15 μl aliquots at -20°C.  
   
5010 Medium   
Sucrose 30 g  
NaNO3 2 g  
KH2PO4 1 g  
MgSO4 x 7 H2O 0.5 g  
KCl 0.5 g  
FeSO4 x 7 H2O 0.01 g  
dH2O 1000 ml  
   
Set to pH 7.8 then autoclave for 20 minutes at 
120°C. 
   
5288 Medium   
Glycerol 15 g  
Soy Meal 10 g  
NaCl 5 g  
CaCO3 1 g  
CoCl2 x 6 H2O 0.001 g  
dH2O 1000 ml  
   
Set to pH 7.8 then autoclave for 20 minutes at 
120°C. 
   
5321 Medium   
Peptone 10 g  
Glucose 20 g  
CaCO3 2 g  
CoCl2 x 6 H2O 0.001 g  
dH2O 1000 ml  
   
Set to pH 7.8 then autoclave for 20 minutes at 
120°C. 
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5333 Medium 
Yeast Extract 4 g  
Soluble Starch 15 g  
KH2PO4 1 g  
MgSO4 x 7 H2O 0.5 g  
dH2O 1000 ml  
   
Set to pH 7.8 then autoclave for 20 minutes at 
120°C. 
 
2.3 Stock Solutions 
PCR Mixes 
PCR mixes N7 and N9 were used in this project. These are mixes from Master AmpTM, High 
Fidelity, Extra-Long PCR Kit, from Epicentre Biotechnologies. 
TMS 1 (Filter 
sterilized) mg/l 
FeSO4*7H2O 5000 
CuSO4*5H2O 390 
ZnSO4*7H2O 440 
MnSO4*H2O 150 
Na2MoO4*2H2O 10 
CoCl2*6H2O 20 
HCl 50 ml/l 
  
Glycerol 20%  
Glycerol 200 ml 
dH2O 800 ml 
  
MgCl2 - 1M  
MgCl2  203.3 g 
dH2O 1 l 
  
Tris HCl 1 M - pH 8.0  
Tris 121.14 g 
dH2O 1 l 
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TfBI Solution (500 ml)  
Potassium Acetate 1.47 g 
MnCl2 4.95 g 
RbCl 6.05 g 
CaCl2 0.74 g 
Glycerol 75 ml 
pH 5.8 with 0.2 M Acetic Acid 
Filter sterilize and store at 4°C 
  
TfBII Solution (100 ml)  
100 mM MOPS pH 7.0 10 ml 
CaCl2 1.10 g 
RbCl 0.12 g 
Glycerol 15 ml 
Autoclave and store at 4°C in the dark 
 
2.4 Primers 
2.4.1 pMoeD Construct 
PCR for pSOK808 part 
Forward primer: 
5‘ – GCGCATCGTATGCGCTCTTCGGTGAACTTCGCACTTCG – 3‘ 
Reverse primer: 
5‘ – CCTCTAGAGTCCGTCTGACGCGTGTGGGCCTTCCGCGAGAAGTTACG – 3‘ 
PCR for A part 
Forward primer: 
5‘ – TCTGACGCGTGTGGGCCTTCCGCGAGAAGTTACGG – 3‘ 
Reverse primer: 
5‘ – GTCGACGTATCCGGCCATCAGGTTCCTTCGCCGAAT – 3‘ 
PCR for B part 
Forward primer: 
5‘ – CCGGCCATCAGGTTCCTTCGCCGAATCCGTACTGG – 3‘ 
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Reverse primer: 
5‘ – GCCCAGAAGGAGCGCATCGTATGCGCTCTTCGGTGAA – 3‘ 
2.4.2 C1R4 Regulator Construct 
PCR for pSOK806 part 
Forward primer: 
5‘ – GGATTTCCTGACCACCTGCAGGTCGACTCTAGAGGATCCG – 3‘ 
Reverse primer: 
5‘ – GGACAATCGTGCCGGTTGGTAGGATCCATGAGTATTCGTCACCG – 3‘ 
PCR for C1R4 regulator part 
Forward primer: 
5‘ – GCCGGTTGGTAGGATCCATGAGTATTCGTCACCGGTGAGCCC – 3‘ 
Reverse primer: 
5‘ – CCGTCGGAGTGGATTTCCTGACCACCTGCAGGTCGACTCTAGAGGA – 3‘ 
2.4.3 C1R5 Regulator Construct 
PCR for pSOK806 part 
Forward primer: 
5‘ – GAGACCGTTCTCTCTGCAGGTCGACTCTAGAGGATCCG – 3‘ 
Reverse primer: 
5‘ – GGACAATCGTGCCGGTTGGTAGGATCGATCAGCAGCCGATC – 3‘ 
PCR for Regulator part 
Forward primer: 
5‘ – GGTTGGTAGGATCGATCAGCAGCCGATCAGTACGGTTGG – 3‘ 
Reverse primer: 
5‘ – CCGGCGTGATCAGAGACCGTTGTCTCTGCAGGTCGACTC – 3‘ 
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2.4.4 C28R Regulator Construct 
PCR for pSOK806 part 
Forward primer: 
5‘ – GGTTGATGAGTTCGTCGTCGTCCTGCAGGTCGACTCTAGAGGATCCG – 3‘ 
Reverse primer: 
5‘ – GGACAATCGTGCCGGTTGGTAGGATCCACCACAACTGCTGG – 3‘ 
PCR for Regulator part 
Forward primer: 
5‘ – CGGTTGGTAGGATCCACCACAACTGCTGGTCCGGC – 3‘ 
Reverse primer: 
5‘ – GGTTGATGAGTTCGTCGTCGTCCTGCAGGTCGACTCTAGAGG – 3‘ 
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3 Methods 
3.1 In Silico Mining 
The online resource tool AntiSMASH 2.0 (http://www.secondarymetabolites.org/) was used for 
the identification of secondary metabolite gene clusters of S. bambergiensis.  
Uploading the whole genome sequence of S. bambergiensis, showed that the bacteria contains 
29 gene clusters.  
Using a combination of antiSMASH, Excel and the online database the National Centre for 
Biotechnology Information (NCBI), (http://www.ncbi.nlm.nih.gov/), an annotation of all the 
clusters was made. Each putative gene was blasted in the NCBI databank and the gene with the 
highest homology was inserted into the Excel sheet (See Annex 1). 
3.2 Storage of Bacterial Strains 
All bacterial strains were stored at -80°C in 20% glycerol stocks. 
Spore suspensions from plates with freshly sporulated S. bambergiensis were prepared as 
follows: 
1. 5 ml of 20% glycerol was poured on the plate 
2. Using a sterile pipette tip, the surface of the plate was gently scratched so as to get the spores 
suspended 
3. Suspension was then drained of the plate and filtered through sterile cotton 
4. Spore suspensions were stored at -80° C 
Thawing of Streptomyces strains was always done on ice as strains will soon lose viability if 
germination starts. (Kieser T. , Bibb, Chater, & Hopwood, 2000) 
3.3 Preparation of Antibiotic Stock Solutions 
Antibiotics stock solutions were prepared as follows: 
Apramycin or Am100 was prepared by mixing 100 mg of Apramycin with 1 ml of dH2O. 
Ampicillin or Amp100 was prepared by mixing 100 mg of Ampicillin with 1 ml of dH2O. 
Thiostrepton or Thio30 was prepared by mixing 30 mg of Thiostrepton with 1 ml of DMSO. 
Nalidixic Acid or Nal30 was prepared by mixing 30 mg of Nalidixic Acid with 1 ml of 0.1 M 
NaOH. 
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Chloramphenicol or Cml25 was prepared by mixing 25 mg of Chloramphenicol with 1 ml of 
Ethanol absolute. 
Kanamycin or Kan25 was prepared by mixing 25 mg of Kanamycin with 1 ml of dH2O. 
Stock solutions were stored in aliquots at -20°C. 
3.4 Preparation of Competent Cells 
In nature, competent bacteria are able to take up exogenous DNA which possibly leads to 
genetic transformation. Artificial competence can be achieved by altering the permeability of 
the cell membrane. (Chen & Dubnau, 2004) 
20 ml of LB was inoculated with a single colony of XL1-Blue or ET12567, and incubated at 
37°C on a shaker overnight. 
This culture was transferred to 300 ml pre-warmed LB media and grown for another two hours 
in shaking incubator at 37°C until the OD at 600 nm reached 0.3 – 0.4. 
Culture was kept on ice from this point on. 
Cells were chilled for 5 minutes on ice and then transferred into six chilled 50 ml tubes. The 
tubes were centrifuged for 10 minutes at 4000 rpm at 4° in a table top centrifuge. Supernatant 
was discarded, and each pellet resuspended in 15 ml of chilled TfBI media. 
Tubes were incubated on ice for 30 minutes, then centrifuged for 10 minutes at 4000 rpm at 
4°C and supernatant discarded. Each pellet was resuspended in 1 ml of chilled TfBII media. 
Aliquots of 100 μl were snap frozen using dry ice and stored at -80°C. 
3.5 Extraction of Plasmid DNA from Bacteria 
Extraction of plasmid DNA from bacteria was done using the kit Wizard Plus SV Minipreps 
DNA Purification System.  
Bacteria with plasmid of interest would be incubated in LB liquid medium overnight at 37°C 
on a shaker. The next day the overnight cultures would be centrifuged for 5 minutes at 10,000 
rpm. The supernatant was discarded and the pellet was resuspended in 250 μl of cell 
Resuspension solution. 250 μl of cell Lysis solution was added to the sample and the tube was 
inverted 4 times to mix. 10 μl of Alkaline protease solution was added and the tube was inverted 
4 times to mix. The tube was incubated for 5 minutes at room temperature. 350 μl of 
Neutralization solution was added and the tube was inverted 4 times to mix. The tube was 
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centrifuged for 10 minutes at 10,000 rpm. A spin column was placed in a collection tube and 
the cleared lysate was decanted into the spin column. The spin column was centrifuged for 1 
minute at 10,000 rpm at room temperature. Flow through was discarded and column was 
reinserted into collection tube. 750 μl of Washing solution was added onto column. Column 
was centrifuged for 1 minute at 10,000 rpm. Flow through was discarded and column reinserted 
into collection tube. This step was repeated with 250 μl Washing solution. Column was 
centrifuged for 2 minutes at 10,000 rpm. Spin column was transferred to a sterile 1.5 ml micro 
centrifuge tube. 100 μl of sterile, nuclease-free water was added to the spin column. Column 
was centrifuged for 1 minute at 10,000 rpm at room temperature. Column was discarded and 
sample was stored at -20°C.  
3.6 Isolation of Total (Genomic) DNA 
Isolation of total DNA of S. bambergiensis wild type and S. bambergiensis moenomycin 
deletion mutant was done using the Qiagen Dneasy Kit.  
Spores were inoculated in 2 ml TSB medium and incubated at 30°C on shaker overnight. Next 
day, 1 ml of the culture was transferred into an eppendorf tube, mixed with 0.5 ml sterile water, 
and spun down at 13,000 rpm for 3 minutes. The supernatant was discarded, and the pellet was 
resuspended in 180 μl lysis buffer (See Materials chapter). Lysozyme was added just before the 
experiment. The mixture was incubated at 37°C for 15 minutes and the suspension mixed gently 
by tipping the end of the tube every 5 minutes. 25 μl of Proteinase K was added and mixed by 
pipetting, then 200 μl of Lysis buffer (AL) was added and mixed by pipetting. The mixture was 
incubated at 55° for 30 minutes. 200 μl of 96% ethanol were added, mixed well by pipetting, 
and then applied on a column sitting in a 2 ml collection tube. The column was centrifuged for 
2 minutes at 13,000 rpm, and transferred to a new 2 ml tube. 500 μl of Washing buffer (AW1) 
was applied on the column and spun for 1 minute at 13,000 rpm. The column was transferred 
to a new 2 ml tube and 500 μl of Washing buffer (AW2) was applied on the column and spun 
for 3 minutes at 13,000 rpm. The column was then transferred into a new eppendorf tube and 
125 μl of Elution buffer (AE), preheated to 50°C, was applied. This tube was incubated at room 
temperature for 15 minutes, and centrifuged for 1 minute at 13,000 rpm. 
The DNA was then checked using gel electrophoresis. 
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3.7 Gel Electrophoresis 
Gel electrophoresis was used in this project to check the size of DNA fragments and also to 
confirm the presence of a product. 0.8% agarose with Gel Green stain was used to prepare the 
gels. 
3.8 Excision and Purification of DNA from Agarose Gels 
PCR products were excised from agarose gels in order to purify the DNA product, so it could 
be used in the Gibson assembly. QIAquick Gel extraction kit was used.  
PCR products were applied on agarose gels and run on 110V for 60-80 minutes. The gel was 
placed inside the Gel Doc imager and photographed. Ultra violet light was used to see the PCR 
products on the gel. The correct DNA products were excised from the gel using a clean, sharp 
scalpel. The slice was placed in an eppendorf tube and weighed. 3 volumes of the buffer QG 
were added for every 1 volume of gel. For example if the slice was 150 mg, then 450 μl of QG 
buffer was added. The eppendorf containing the slice and buffer were incubated at 50°C for 10 
minutes, vortexed every 3 minutes during incubation. When the slice was completely dissolved, 
1 gel volume of isopropanol was added and mixed. QIAquick spin columns were placed in 2 
ml collection tubes. The sample from the eppendorf was applied on the column and it was 
centrifuged for 1 minute on 13,000 rpm. Flow through was discarded and QIAquick column 
was placed back in the same collection tube. 750 μl of PE buffer was added onto the column 
and it was centrifuged for 1 minute on 13,000 rpm. Flow through was discarded and the column 
was centrifuged for an additional 1 minute on 13,000 rpm. The column was placed in a sterile 
eppendorf tube and 50 μl of EB buffer was applied to the centre of the column membrane and 
then it was centrifuged for 1 minute on 13,000 rpm. This sample was then checked on a gel to 
confirm correct size. The product was stored at -20°C. 
3.9 Gibson Assembly 
All assemblies of DNA fragments were carried out using the Gibson assembly method.  
The Gibson assembly is an isothermal, single reaction method (Figure 6). It is used to assemble 
DNA fragments with overlapping regions. This method uses 5´ exonucleases, Phusion DNA 
polymerase and Taq DNA ligase. Having two adjacent DNA fragments that share terminal 
sequence overlaps, they can be joined into a covalently sealed molecule in a one-step isothermal 
reaction. T5 exonuclease removes nucleotides from the 5’ ends of double stranded DNA 
molecules. The 3’ complementary single-stranded DNA overhangs then anneal and the Phusion 
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DNA polymerase fills the gaps and Taq DNA ligase seals the nicks. T5 exonuclease is heat-
labile and is inactivated during the 50°C incubation. (Gibson, et al., 2009) 
 
Figure 6: The Gibson assembly is an isothermal reaction. Two adjacent fragments (magenta 
and green) share terminal sequence overlaps (black). These fragments are joined into a 
covalently sealed molecule. T5 exonuclease removes nucleotides from the 5' ends of the double-
stranded DNA molecules. Complementary single-stranded DNA overhangs anneal and Phusion 
DNA polymerase fills the gaps and Taq DNA ligase seals the nicks. T5 exonuclease is heat-
labile and is inactivated during the 50°C incubation. (Gibson, et al., 2009) 
All vectors were first treated with a DpnI restriction enzyme. DpnI cuts methylated DNA. The 
pSOK806 and pSOK808 templates used in the PCR contain methylated DNA. DpnI treatment 
chews up the template plasmid but not the PCR product. (Zhng, Baumann, & Reymond, 2004) 
For the DpnI treatment of the vector parts, 14 μl of purified PCR vector product, 2 μl Cutsmart 
10X Buffer, 1 μl DpnI enzyme and dH2O up to 20 μl, were mixed in an eppendorf tube and 
placed in a PCR machine. The program for the DpnI treatment is shown in the following table 
(Table 3). 
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Table 3: Program for DpnI treatment of vector part. 
Step 
Temperature  
(° C) 
Duration 
(Minutes) 
1. 37 60 
2. 80 20 
3. 4 Forever 
 
The Gibson reaction for the moenomycin deletion vector consisted of 15 μl of Gibson mix, 0.5 
μl of DpnI treated vector part, 2.5 μl of PCR amplified part A and 2.0 μl of PCR amplified part 
B. 
The Gibson reaction for the regulator parts consisted of 15 μl of Gibson mix, 1 μl of DpnI 
treated vector, and 4 μl PCR amplified DNA for the regulatory gene. 
The program used in the PCR machine for the Gibson assembly method is shown in the 
following table (Table 4). 
Table 4: Program for Gibson assembly. 
Step 
Temperature  
(° C) 
Duration 
(Minutes) 
1. 50 60 
3. 4 Forever 
 
3.10 Transformation 
Transformation is the incorporation of foreign DNA into bacterial cells. In this work plasmid 
vectors were introduced into competent XL1-Blue E. coli cells. XL1-Blue gives high yields of 
transformants but as many Streptomyces strains possess a restriction system that cuts 
methylated DNA, a totally non-methylating E. coli host is needed as a DNA donor for 
conjugation. (Kieser T. , Bibb, Buttner, Chater, & Hopwood, 2000) 
DNA constructs made in this work, by Gibson assembly, were transformed into XL1-Blue cells 
and the plasmids were isolated, and analysed by restriction analysis. Confirmed by Gel 
Electrophoresis, constructs were transformed into the non-methylating ET12567 E. coli cells. 
Competent cells were taken from -80°C storage and placed on ice for 5 minutes. 1 μl of relevant 
plasmid DNA was added, mixed by tapping the tube with a finger and placed back to ice for 15 
minutes. The tube was then transferred to a thermoblock at 42°C for 1 minute for heat shock 
and set back to ice for 2 – 10 minutes. 800 μl of LB media was added, and the tube placed into 
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shaking incubator at 37°C for 40 minutes to 2 hours. 100 μl of the suspension was plated on LA 
plates with appropriate antibiotics for selection. 
Plates were placed in 37°C for overnight incubation.  
3.11 Conjugation 
Bacterial conjugation involves the direct transfer of DNA from a donor cell to a recipient cell 
through a specialized intercellular channel, which forms between them. (Snustad & Simmons, 
2012)  
In this work, the E. coli strain, ET12567 with helper plasmid pUZ8002 was used for 
conjugation. This is a non-methylating strain. A totally non-methylating E. coli cell is needed 
as a DNA donor for conjugation as many Streptomyces contain a methyl specific restriction 
system. (Kieser T. , Bibb, Chater, & Hopwood, 2000) After successful transformation of 
plasmid into E. coli strain ET12567, conjugation into Streptomyces could proceed. The 
conjugation process transferred the plasmid into the Streptomyces species. Transferred plasmid 
integrates into host genome by way of homologous recombination.  
Transfer of DNA from donor cell to recipient cell is initiated at the oriT site (Origin of Transfer) 
on the plasmid. During conjugation, one strand of the plasmid is cut at the oriT by an enzyme 
and one end is transferred into the recipient cell through a channel that forms between the two 
conjugating cells. (Snustad & Simmons, 2012) 
Conjugations in this work involved the plasmids pSOK808 for deletion of moenomycin and 
pSOK806 for overexpression of regulators. (Sekurova, et al., 2004) 
 
 
 
 
 
 
 
30 
 
Plasmid pSOK808 contains an RP4 oriT site for initiation of transfer, Amr to confer resistance 
to apramycin and a gusA site for gusA assays (See Figure 7).  
Plasmid pSOK806 contains an RP4 oriT site for initiation of transfer, Amr to confer resistance 
to apramycin, attP site and integrase gene for site specific integration and an ermE*p up strong 
constitutive promoter region for overexpression of regulators (Figure 8). 
The day before conjugations, overnight cultures of ET12567 cells were prepared on appropriate 
selection plates.  
The next day spore suspensions of Streptomyces strains were taken from -80°C storage and 
thawed out on ice. 50 μl of this spore suspension was added into 350 μl of 2 X YT media. This 
suspension was put for 5 – 10 minutes at 50°C for heat shock, and then allowed to cool down 
at room temperature for 10 – 15 minutes. 
Figure 7: Plasmid pSOK808 was used for deletion of moenomycin gene cluster. The part of the 
plasmid used in this project contains an RP4 oriT site, AmR site and a gusA site. 
Figure 8: Plasmid pSOK806 was used for overexpression of regulator parts. The part of the 
plasmid used in this project contains an RP4 oriT site, AmR, attP site and integrase gene and 
an ermE*p up strong constitutive promoter region. 
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An area (ca. 1.5x1.5 cm) of the ET12567 cells from fresh selective plate was swiped and 
suspended in 500 μl of 2 X YT media.  
400 μl of the heat shocked Streptomyces and 100 μl of ET12567 cell suspension were mixed 
carefully by pipetting, and then spun down for 1 min at 5000 rpm. 350 μl of supernatant was 
removed and the remaining suspensions plated on dry ISP4 + MgCl2 plates. Then stored at 30° 
for 18 – 20 hours.  
18 – 20 hours later selection for recombinant Streptomyces was done by adding on each plate 1 
ml dH2O + 30 μl of Nal30 and 15 μl of Am100, gently rubbed into media and let dry out for about 
20 minutes. Incubation continued for 2 – 3 days at 30°C.  
Transconjugants were picked with sterile toothpicks and plated on new ISP4 with Nalidixic 
acid and another appropriate antibiotic for selection of Streptomyces. This was further incubated 
for about 3 – 4 days or until good growth was observed. The most visibly viable colonies were 
transferred to new ISP4 with appropriate antibiotic and incubated until sporulation. 
Spore suspensions of recombinant Streptomyces strains were made and stored at -80°C for 
further analysis. 
3.12 Construction of S. bambergiensis Moenomycin Deletion Mutant 
In order to get a clear background for the detection of novel secondary metabolites, a S. 
bambergiensis moenomycin deletion mutant was needed, as S. bambergiensis is a known 
producer of the antibiotic moenomycin. 
The moenomycin gene cluster was identified using the online resource tool, AntiSMASH 2.0 
(See Method 3.1). (Blin, et al., 2013) 
A strategy was devised for the deletion of the scaffold genes for moenomycin production, where 
primers were designed for two regions, A and B, which flank the moenomycin gene cluster. 
These regions were then PCR amplified and cloned into a vector, pSOK808, using the Gibson 
assembly method. This vector was then introduced into the E. coli cells by transformation and 
these cells were then in turn conjugated to the wild type S. bambergiensis.  
Following a double crossover event, the moenomycin deletion mutant was made (Figure 9). 
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Figure 9: Schematic of moenomycin deletion strategy. Using designed primers, part of the 
plasmid pSOK808 was amplified using PCR and also A and B, flanking the moenomycin gene 
cluster in S. bambergiensis. Using the Gibson assembly method, these 3 parts were assembled 
and introduced into E. coli cells via transformation and then into S. bambergiensis via 
conjugation. Single and double crossover events would then later occur as explained in detail 
in the text. For the S. bambergiensis moenomycin deletion mutant, a scar of A + B parts would 
be observed. 
A more detailed explanation of the method follows. 
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Using the j5 program (https://j5.jbei.org/) and Clone Manager, primers were designed for 
amplifying the flanking regions, A and B, of the moenomycin gene cluster. Primers were also 
designed for the vector pSOK808. The part of the pSOK808 vector contained the Amr region 
and the gusA reporter gene. The following program was used for the PCR amplification (Table 
5). 
Table 5: PCR program used to amplify regions A and B of the moenomycin gene cluster and 
also for the pSOK808 vector part. 
Step 
Temperature 
(° C) Duration 
Number of 
cycles 
1. 95 3 minutes   
2. 94 
45 
seconds 
x25 
3. 56 
45 
seconds 
4. 68 
10 
minutes 
5. 68 
10 
minutes   
6. 4 Forever   
 
The PCR consisted of 1 μl DNA, 0.5 μl of each primer, 20 μl master mix (N7 for A and B parts, 
N9 for pSOK808), (See Materials, Stock Solutions), 0.8 μl polymerase Q5 and dH2O up to 40 
μl. 
The PCR product of vector part was treated with DpnI before assembly. For the DpnI treatment, 
14 μl of purified PCR vector product, 2 μl Cutsmart 10X Buffer, 1 μl DpnI enzyme and dH2O 
up to 20 μl, were mixed in an eppendorf tube and placed in a PCR machine. The program for 
the DpnI treatment PCR is shown in the following table (Table 6). 
Table 6: PCR program for DpnI treatment of pSOK808 vector part. 
Step 
Temperature  
(° C) 
Duration 
(Minutes) 
1. 37 60 
2. 80 20 
3. 4 Forever 
 
These three parts were then assembled using the Gibson assembly method (Gibson, et al., 2009). 
The volume of the Gibson reaction was 20 μl and consisted of 15 μl Gibson Mix, 0.5 μl of 
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vector (pSOK808) DNA, 2.5 μl of A part DNA and 2.5 μl of B part DNA. This was gently 
mixed and a reaction was performed using the following program (Table 7). 
Table 7: Program for the Gibson assembly reaction of pMoeD. 
Step 
Temperature 
(° C) Duration 
1. 50 
60 
minutes 
2. 4 Forever 
 
A figure of the J5 software generated pMoeD molecule can be seen in the following figure 
(Figure 10). 
 
Figure 10: J5 software representation of the moenomycin deletion construct pMoeD. 
This construct was transformed into XL1-BLue competent cells, using the transformation 
procedure as explained in the methods (See Method 3.10). 
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Next step was the plasmid isolation from the transformed XLBlue1 cells (See Method 3.5). 
Restriction analysis was done to confirm the correct clone using BamHI (See Method 3.14). 
Restriction assay consisted of 2 μl of DNA, 2 μl of NEB buffer 3.1, 0.8 μl of BamHI and dH2O 
up to 20 μl. 
After confirming the correct construct, the plasmid, designated as pMoeD, was then 
transformed into competent ET12567 cells using the transformation method (See Method 3.10). 
PMoeD was then conjugated into the wild type S. bambergiensis, as described in the methods 
(See Method 3.11). 
Once the single crossover had occurred, the S. bambergiensis with pMoeD integrated into its 
chromosome, had attained an Amr, and can be selected on ISP4 plates with Am. Crossover 
mutants were selected to obtain double crossover mutants. For this purpose 3 rounds of 
sporulation on the ISP4 plates without selection with following gusA assay were performed 
(See Method 3.13). 
After 3 full rounds of sporulation, spore suspension was plated on ISP4 with appropriate 
antibiotic as explained in methods. Those colonies that hadn´t gained a blue colour were 
checked for sensitivity for Am, as the double crossover S. bambergiensis would have lost their 
Amr. 
The genomic DNA from the colourless, Am sensitive colonies was then isolated using the DNA 
isolation method (See Method 3.6) 
To confirm the 2nd crossover candidates, a PCR was performed using forward primer of the A 
part and reverse primer of the B part. The plasmid pMoeD was used as a template for positive 
control in the reactions. 
For this PCR, 1 μl of genomic/plasmid DNA was used, 0.5 μl of each primer, 20 μl of N7 PCR 
mix, 0.8 μl of Q5 Polymerase and dH2O up to 40 μl. The program used was as follows (Table 
8). 
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Table 8: PCR program used for confirmation of moenomycin deletion mutant. 
Step 
Temperature 
(° C) Duration 
Number of 
cycles 
1. 95 
60 
minutes   
2. 94 
45 
seconds 
x25 
3. 56 
45 
seconds 
4. 68 
10 
minutes 
5. 68 
10 
minutes   
6. 4 Forever   
 
3.13 GusA Assay for Selection of Second Crossover Mutant 
GusA, encoding enzyme β-glucuronidase (GusA) is a reporter gene which is a part of the 
pSOK808 vector used in this research. GusA converts the substrate, 5-bromo-4-chloro-3-
indolyl β-D-glucuronide cyclohexylammonium salt, and cells appear blue on media plates 
(Figure 11). (Siegl & Luzhetskyy, 2012) 
 
Figure 11: Using Gibson assembly, genes A and B, flanking the moenomycin gene cluster, were 
cloned into the pSOK808 vector. pSOK808 contains the gusA reporter gene. When this plasmid 
is inserted into the moenomycin gene cluster via single crossover, the cell gains the ability to 
utilize the added substrate and turn blue. During a double crossover event, the cells lose this 
ability and remain white. In this way the cells that have the desired deletion can easily be 
selected. (Siegl & Luzhetskyy, 2012) 
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Several dilutions of spore suspensions of candidate for second crossover were made in order to 
obtain single colonies on a plate for GusA assay. 1 ml of sterile dH2O was added to 7 eppendorf 
vials. 100 μl of S. bambergiensis MoeD second crossover mutants were added to the first one 
and mixed by pipetting. 100 μl from the first eppendorf was added to the second and mixed and 
so on, until a dilution series up to -7 was reached. Dilutions -5, -6 and -7 were plated and dilution 
-5 was selected as the most appropriate as a colony count of around 200 colonies was observed. 
3 tablets of 5-bromo-4-chloro-3-indolyl β-D-glucuronide cyclohexylammonium salt (GusA 
substrate) were added to 300 μl of dH2O. This was vortexed until completely dissolved. This 
was added to 300 ml of autoclaved ISP4 medium, mixed and poured onto plates. 
150 μl of -5 dilution of S. bambergiensis candidate for 2nd crossover (moenomycin deletion 
mutant), was spread on plates w. added GusA substrate, and incubated at 30°C. Daily 
observations ensued. After 3 days of incubation, 8 non-blue colonies were selected and checked 
for Am sensitivity. 
3.14 Construction of Vector for Overexpression of Regulatory Gene from S. 
bambergiensis  
In order to overexpress a regulatory gene from S. bambergiensis, it was cloned into the 
integrative vector under the control of strong constitutive promoter ermE*p, and introduced 
into moenomycin deletion mutant (Figure 12). (Sezonov, Duchene, Friedman, Guerineau, & 
Pernodet, 1998)  
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Figure 12: Once regulator part is integrated with the pSOK806 vector part, the vector for 
overexpression of regulatory gene is complete. The vector for overexpression of regulatory 
gene contains an integrase gene and an attP site, along with the strong constitutive promoter 
ermE*p, regulatory gene, AmR (apramycin resistance) and the oriR (origin of replication). 
With the aid of an integrase enzyme, the attP site of the construct recombines with the attB site 
on the target genome. 
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Using AntiSMASH, regulators were selected for over expression (See Method 3.1). Regulatory 
genes 4 and 5 from cluster 1 and the single regulator from cluster 28, designated as C1R4, C1R5 
and C28R, respectively, were chosen for this experiment. 
Primers for amplifying the regulators and the pSOK806 vector, were designed using the online 
program j5 (https://j5.jbei.org/) and the Clone Manager software. 
PCR amplification for the pSOK806 vector was performed  using 0.5 μl pSOK806 DNA, 20 μl 
N9 enzyme mix (see appendix), 0.8 μl of polymerase Q5, 0.5 μl forward primer, 0.5 μl reverse 
primer and dH2O up to 20 μl 
PCR amplification for the regulators was performed using 1 μl of S. bambergiensis total DNA, 
20 μl N7 PCR mix, 0.8 μl of polymerase Q5, 0.5 μl forward primer, 0.5 μl reverse primer and 
dH2O up to 20 μl. 
The PCR program used was as follows (Table 9). 
Table 9: PCR program used for amplification of regulatory genes and pSOK806 parts. 
Step 
Temperature 
(° C) Duration 
Number of 
cycles 
1. 95 
60 
minutes   
2. 94 
45 
seconds 
x25 
3. 56 
45 
seconds 
4. 68 
10 
minutes 
5. 68 
10 
minutes   
6. 4 Forever   
 
Gel electrophoresis was performed using 0.8% agarose containing Gel Green. DNA stain. The 
gel was run on 100V for 1 hour.  
Bands were cut out of the gel and purification of DNA was performed as explained in the 
methods (See Method 3.8). 
The purified DNA fragments were then assembled via Gibson assembly method (See Method 
3.9) 
40 
 
The vector parts were all treated with DpnI before assembly. For the DpnI treatment of the 
vector parts, 14 μl of purified PCR vector product, 2 μl Cutsmart 10X Buffer, 1 μl DpnI enzyme 
and dH2O up to 20 μl, were mixed in an eppendorf tube and placed in a PCR machine. The 
reaction was performed as it is shown in the following table (Table 10). 
Table 10: Program for DpnI treatment of pSOK806 vector part. 
Step 
Temperature 
 (° C) 
Duration 
(Minutes) 
1. 37 60 
2. 80 20 
3. 4 Forever 
 
The two parts were then assembled using the Gibson assembly (Gibson, et al., 2009). The 
volume of the Gibson reaction was 20 μl and consisted of 15 μl Gibson Mix, 1 μl of the vector 
(pSOK806) DNA, 4 μl of the regulatory gene DNA. This was gently mixed and an isothermal 
Gibson reaction was performed as in the following table (Table 11). 
Table 11: PCR program for the Gibson assembly reaction of regulators 
Step 
Temperature 
(° C) 
Duration 
(Minutes) 
1. 50 60  
2. 4 Forever 
 
These constructs were transformed into XL1BLue competent cells, using the transformation 
procedure as explained in the methods (See Method 3.10) 
Next step was the plasmid isolation from the transformed XL1Blue cells (See Method 3.5). 
Restriction analysis was done to confirm the correct clone. 
Restriction assay was done with various restriction enzymes and it consisted of 2 μl of DNA, 2 
μl of NEB buffer 3.1, 0.8 μl of each restriction enzyme and dH2O up to 20 μl. 
The restriction enzyme used for C1R4 construct was PvuII. For C1R5 construct, EcoRI and 
NhEI were used. For C28R construct, EcoRI was used. 
After confirming the correct constructs (See Figure 13), they were transformed into competent 
ET12567 cells as described in the methods (See Method 3.10). 
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Conjugations with the ET12567 cells w. regulator constructs and the S. bambergiensis MoeD 
followed. The conjugation was carried out as described in the methods (See Method 3.11). 
Mutants containing integrated vectors for overexpression of regulatory genes were designated 
S. bambergiensis MoeD C1R4, S. bambergiensis MoeD C1R5 and S. bambergiensis MoeD 
C28R. 
Spore suspensions were made of all mutants and stored at -80°C. 
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Figure 13: Assembled regulator constructs containing the attachment site, ermE*p strong 
constitutive promoter, the regulatory gene, origin of replication, AmR and the integrase gene. 
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3.15 Specific Digestion of DNA by Use of Restriction Endonucleases 
In order to confirm that the plasmid constructs made in this project were the correct ones, 
restriction endonucleases were used to cut the constructs. Using Clone Manager, appropriate 
restriction enzymes were chosen, based on the plasmids recognition sites, to cut the molecules 
into 2 – 3 fragments. The fragments were then applied to a gel and separated.  
Restriction enzymes are naturally produced by bacteria in order to defend against infection by 
viruses or other mobile genetic elements (MGEs). They do this by degrading the DNA of the 
MGEs. The restriction enzyme binds to DNA at a specific sequence of nucleotides or what is 
called the recognition sequence. The enzyme cuts both strands of the DNA within the sequence 
producing restriction fragments (Figure 14). (Klug, Cummings, Spencer, & Palladino, 2009) 
 
Figure 14: This figure shows how a restriction enzyme cleaves a DNA molecule. In this case 
leaving sticky ends. (Image taken from 
http://biotechlearn.org.nz/themes/dna_lab/images/restriction_enzyme) 
Most restriction sequences are palindromes. Which means that the nucleotide sequence reads 
the same on both strands of the DNA molecule when read in the 3’ to 5’ direction. (Pingoud & 
Jeltsch, 2001) 
2.0 ml of CutSmart Buffer, 0.8 ml of restriction enzyme, 3 ml of DNA and dH2O up to 20 ml 
was pipetted to eppendorf tubes. These tubes were placed in 37° for 2 hours. Gel electrophoresis 
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was performed using 0.8% agarose containing Gel Green. DNA stain. The gel was run on 100V 
for 1 hour. 20 μl of sample, 3.5 μl of dye and 3 μl of ladder were used. 
3.16 Primer Design 
Primer design was done using the program Clone Manager version 6.0 and then the online 
resource j5.jbei.org. 
3.17 Growth Inhibition Bio Assay 
In order to get a first indication of any antimicrobial activity of the Streptomyces MoeD mutants, 
a growth inhibition bio assay was performed.  
3.17.1 Bioassay with Prokaryotic and Eukaryotic Strains 
E. coli (Gram - prokaryote), Bacillus subtilis (Gram + prokaryote) and Saccharomyces 
cerevisiae (eukaryote), were chosen as test organisms for bioassay. 
E. coli and B. subtilis cells were incubated overnight in 2 ml of LB media at 37°C and S. 
cerevisiae was incubated overnight in 2 ml of YPD liquid media at 30°C. 
3.17.2 Fermentations 
100 μl of spore suspension from S. bambergiensis wild type, S. bambergiensis MoeD, S. 
bambergiensis MoeD C1R4, S. bambergiensis MoeD C1R5 and S. bambergiensis MoeD C28R 
were inoculated in 10 ml of medium 2XYT and incubated for 48 hours in shaking incubator at 
30°C, 250 rpm. 
After 48 hours, 2 ml of culture were inoculated into 50 ml of fermentation medium in 250 ml 
baffled flasks. These flasks were placed in a shaking incubator at 30°C, 250 rpm and incubated 
for 6 days. 
3.17.3 Methanol Extractions 
For methanol extractions, S. bambergiensis MoeD and S. bambergiensis MoeD C28R were 
fermented. For this purpose, 1 ml of each of the 6 day fermentations in different fermentation 
media (S800, 5010, 5288, 5321 and 5333) was placed into 13 ml tubes. These were centrifuged 
for 7 minutes at 8000 rpm. The cell pellet was resuspended in 3 ml of ethanol and glass beads 
were added. The tubes were placed into a shaking incubator at 16°C, 900 rpm for 60 minutes. 
The tubes were then centrifuged at 8000 rpm for 7 minutes. Aproximately 3 ml of supernatant 
was placed into eppendorf tubes.  
100 μl of overnight culture of S. cerevisiae was spread onto a YPD plate. 100 μl of overnight 
cultures of E. coli and B. subtilis, were plated onto LA plates.  
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40 μl of methanol extracts were placed on sterile paper disks, allowed to dry out for 15 minutes 
in a sterile hood, and then the disks were set on the plates with test organism. Plates were then 
incubated overnight at 30°C for S. cerevisiae and 37°C for E. coli and B. subtilis. 
3.17.4 Butanol Extraction 
1 ml of each of the 6 day fermentation (PM4 medium) was placed into 13 ml tubes. 0.5 μl of n-
butanol was added and the tubes were vortexed for 1 minute. The mixes were transferred into 
eppendorf tubes and spun for 3 minutes at 13,000 RPM. About 0.4 ml was taken from the upper 
phase (extracts) placed in new eppendorf tubes. 
3.18 UV Scans 
To get a first indication of novel compound production in recombinant strains, Ultraviolet (UV) 
scans were used.  
Using the 6 day fermentations, 4 ml were extracted and placed in 10 ml tubes. 2 ml of n-butanol 
was added to each tube and they were spun down for 3 minutes at 10,000 RPM. About 1.5 ml 
of the upper phase was moved to eppendorfs.  
S. bambergiensis MoeD was used as reference or control sample.  
1 ml of the upper phase liquid was used for the scan. The scan range was 220 – 650 nm, with a 
step increment of 5 nm. 
S. bambergiensis MoeD C1R4, S. bambergiensis MoeD C1R5 and S. bambergiensis MoeD 
C28R were sampled. 
3.19 HPLC 
Two strains of S. bambergiensis (WT and MoeD) were sent to the University of Napoli for High 
Performance Liquid Chromatography or HPLC.  
HPLC stands for High-Performance Liquid Chromatography. HPLC is a technique used to 
separate, identify and quantify components in a mixture. Sample is run through a column filled 
with solid adsorbent material. Depending on the interaction of the component to the adsorbent 
material in the column, different flow rates for different compounds result and this leads to the 
separation of the components as they flow through the column. (Gerber, et al., 2004) 
At Napoli, the 2 strains were cultivated using PM4 medium (inoculum in TSB + 10% Sucrose). 
An extraction was performed of the culture medium after sonication with BuOH. The organic 
layers were dried, resuspended in MeOH at 10 mg/ml and subjected to LC-MS (Liquid 
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Chromatography-Mass Spectrometry). A 5 μm Kinetex column (100x2.1 mm), maintained at 
room temperature, was used. Injection: 5 μl, Gradient program at 200 μl min-1: 10% MeOH 3 
min, 10-95% MeOH over 25 min, 95% MeOH 15 min. Negative ion mode, m/z 150-2000. 
The BuOH extracts were dried and resuspended in MeOH at 1 mg/ml and subjected to LC-MS 
in the same conditions as above. 
HPLC for the methanol extractions was carried out at the NTNU facilities. Methanol extractions 
from S. bambergiensis MoeD and S. bambergiensis MoeD C28R were analysed. 
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4 Results 
4.1 Genome Analysis for SM Gene Clusters 
Using antiSMASH, an annotation sheet of all the gene clusters was made.  
BLASTing genes in gene cluster 2 showed homology to moenomycin associated genes in the 
well explored moenomycin biosynthetic pathway of S. ghanaensis. (Ostash & Walker, 2010) 
AntiSMASH analysis of S. bambergiensis showed that gene cluster 28 was likely to be a gene 
cluster for biosynthesis of a putative 66-membered macrolide. Cluster 28 is a type I PKS, 
contains 30 genes and spans over 190 kb. This would make it one of the largest polyketide 
biosynthetic gene cluster identified to date. (Laureti, et al., 2011) Gene cluster 28 also contains 
157 enzymatic domains organized into 23 modules. This cluster was specifically selected for 
targeted activation. An antiSMASH representation of the polyketide synthase is seen in the 
following figure (Figure 15). 
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Figure 15: AntiSMASH representation of the polyketide synthase involved in biosynthesis 
of putative macrolide in gene cluster 28. It contains 157 domains contained in 23 modules. 
These all have specific roles in assembling the secondary metabolite scaffold.  
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Cluster 1, a non-ribosomal peptide synthetase (NRPS), was also selected for targeted activation. 
Non-ribosomal peptides are SM and often antibiotics. (Finking & Marahiel, 2004) BLASTing 
genes of gene cluster 1 showed low homology to genes in the NCBI databank. 
4.2 Construction of S. bambergiensis Moenomycin Deletion Mutant 
The construction of the S. bambergiensis moenomycin deletion mutant can be split into 6 main 
steps: 
 PCR amplification of pSOK808 vector part and the A and B parts, flanking the 
moenomycin gene cluster; 
 Gibson assembly of the three parts, transformation of Gibson mix into competent E. coli 
cells and selection of clones containing assembled vector; 
 Transformation of moenomycin deletion vector into non-methylating  E. coli strain ET 
12567 , followed by conjugation  into  S. bambergiensis wild type, and selection of a 
first crossover mutants 
 Propagation of the first crossover mutants without selective pressure for several 
generations 
 GusA assay for selection of second crossover mutant(s) 
 PCR to confirm that the moenomycin gene cluster was deleted. 
 
 
 
 
 
 
 
 
 
 
50 
 
4.2.1 PCR of Vector Part and the A and B parts 
Using the j5 (Hillson, 2011) and Clone manager tools, PCR primers were designed.  
These primers were used in the PCR of pSOK808 vector part and the A and B fragments 
flanking the moenomycin gene cluster. Gel electrophoresis was run to check the PCR products. 
The sizes should be 1703 bp for the A part, 1602 bp for the B part and 5341 bp for the vector 
part (Figure 16). 
4.2.2 Gibson Assembly 
Using the Gibson assembly method (See Method 3.9), the three parts were combined and 
transformed into competent E. coli DH5α cells. Confirmation of the correct clone was done by 
isolating the plasmid DNA and running a restriction analysis using BamHI, which cuts this 
construct at 3 sites and gives three bands of sizes 1022 bp, 1944 bp and 5681 bp on a gel. 
Correct constructs are seen in samples 2, 4 and 7 in the following figure (Figure 17). 
Figure 16: Gel electrophoresis of the A, B and vector parts for the moenomycin deletion vector. 
Part A was 1703 bp, part B 1602 and the vector part (pSOK808) 5341 bp in sizes. 
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Figure 17: Gel picture of restriction assay of moenomycin deletion construct. The restriction 
enzyme used was BamHI, which cuts the correct construct at three sites. Wells are counted after 
the control. In wells 2, 4 and 7 the correct clones were observed. 
Correct plasmid (pMoeD) was transformed into competent E. coli ET12567 cells, where from 
it was conjugated into S. bambergiensis WT. 
4.2.3 Transformation and Conjugation 
Moenomycin deletion vector was transformed into non-methylating E. coli strain, ET12567. 
This was followed by conjugation into S. bambergiensis wild type, and selection of a first 
crossover mutants. 
4.2.4 Propagation of First Crossover Mutants 
Propagation of the first crossover mutants was done without selective pressure for several 
generations as explained in the methods (See Method 3.12). 
4.2.5 GusA Assays 
The insertion of the pMoeD into the chromosome of S. bambergiensis is done via a single 
crossover, where the plasmid is integrated into the DNA of the S. bambergiensis by homologous 
recombination. For the double crossover event, the S. bambergiensis was incubated for three 
rounds of sporulation, as explained in the methods (See Method 3.12). After three rounds, the 
strains were checked for moenomycin deletion by using the GusA assay, as explained in the 
methods (See Method 3.13). 
52 
 
Colonies that had undergone the double crossover event would show no colour in the assay, 
while the ones that remained unchanged and kept the plasmid integrated into the chromosome 
would retain the ability to utilize the GusA substrate, thus turning blue (Figure 18). 
 
Figure 18: GusA assay. The colonies that did not show a blue colour were the ones that had 
putatively undergone the 2nd crossover. They were incubated on new ISP4 plates. 
4.2.6 PCR of “Scar” Region of S. bambergiensis MoeD Double Crossover Mutants 
Using the forward primer for the A part and the reverse primer for the B part, a PCR was done 
using the genomic DNA isolated from cultures representing the white colonies. 
The expected “scar” was 3305 bp in size and the correct clones were confirmed using gel 
electrophoresis of PCR products. The following gel figure (Figure 19) shows that in wells 1, 3 
and 4, the correct PCR product is observed. 
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Figure 19: Gel showing the scar of the moenomycin cluster deletion in wells 1, 3 and 4. This 
scar is about 3300 bp in size and consists of the A + B parts of the original moenomycin gene 
cluster.   Plasmid pMoeD was used as a template for positive control PCR. 
4.3 LC-MS of Butanol Extracts 
The S. bambergiensis moenomycin deletion mutant (MoeD) along with the wild type S. 
bambergiensis (WT) and moenomycin standard (flavomycin) were sent to the University of 
Napoli for liquid chromatography mass spectrometry (LC-MS). This was done to confirm the 
deletion of moenomycin gene cluster in S. bambergiensis. 
Moenomycin has an m/z of 789.8233. Both the flavomycin standard and the S. bambergiensis 
WT showed such peaks. No moenomycin analogue was detected in the MoeD strain as can be 
seen in the following figure (Figure 20). 
 
Figure 20: Moenomycin has an m/z 789.8233. Here a peak for this m/z can be seen at 24 
minutes for the WT and the flavomycin standard. The MoeD mutant strain shows no such peak. 
4.4 Construction of S. bambergiensis Regulator Mutants 
Three S. bambergiensis MoeD mutants,  MoeD C1R4, MoeD C1R5 and  MoeD C28R, have 
been obtained by introduction of vectors, containing regulatory genes under control of strong 
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constitutive promotor ermE*p into S. bambergiensis MoeD mutant strain, non-producer of 
moenomycin.  
Gene cluster 1 contains 5 regulatory genes (See Annex 2). Regulators 4 and 5 were chosen for 
overexpression. Regulator 4 is a LuxR family regulator, a regulatory gene known to be involved 
in the biosynthesis of antibiotics. (Chen & Xie, 2011) Regulator 5 is of the SARP family of 
regulators. SARP family of regulators are known activators of biosynthetic genes in gene 
clusters. (Aigle & Corre, 2012) 
Gene cluster 28 contains 1 regulatory gene (See Annex 2), a LuxR family transcriptional 
regulator. As LuxR family regulators are involved in regulation of many SMs, this was a good 
candidate for overexpression. (Chen & Xie, 2011) 
The construction of the S. bambergiensis regulatory mutants can be split into 3 main categories: 
 PCRs of vector part and regulatory genes 
 Gibson assembly of vector part and regulatory genes, and transformations of assembly 
mixes into E.coli strains 
 Conjugation of confirmed overexpression vectors into S.bambergiensis MoeD strain 
4.4.1 PCR of Vector Part and Regulatory Genes 
Using the j5 programme and Clone manager tools, primers for Gibson assembly were designed.  
These primers were used for the PCR of pSOK806 vector and the regulatory genes.  
Sizes for the respective parts can be seen in the following table (Table 12). 
Table 12: Table showing the respective sizes of each part of the regulator constructs. 
Part 
Full Size 
(bp) 
Regulatory  
Gene 
Size(bp) 
pSOK806 
Part Size 
(bp) 
C1R4 
Construct 
6604 850 5754 
C1R5 
Construct 
7824 2070 5754 
C28R 
Construct 
8805 3051 5754 
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Gel electrophoresis was run to see if the PCR products were of correct sizes (Figures 21 and 
22).  
 
 
Figure 21: Gel electrophoresis of pSOK806 
parts. This figure confirms the sizes of PCR 
products (5754 bp). 
Figure 22: Gel electrophoresis of regulatory 
gene parts. This figure shows the PCR 
products of correct sizes, 850 bp for C1R4, 
2070 bp for C1R5 and 3051 bp for C28R. 
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4.4.2 Gibson Assembly of Vector Part and Regulatory Gene 
Using the Gibson assembly method, the respective two parts were combined and transformed 
into competent E. coli DH5α cells. Confirming the correct clone was done by isolating the 
plasmid DNA and running a restriction analysis using appropriate restriction enzymes. 
Construct pC1R4 was cut with PvuII and this would cut the DNA molecule into two pieces, 
yielding 4578 bp and 2029 bp fragments (Figure 23). 
 
Figure 23: Restriction assay for regulator C1R4. Wells 7 and 8 contain the correct clones as 
they are of appropriate sizes (4575 and 2029 respectively). 
Construct pC1R5 was cut with EcoRI and NhEI and this would cut the DNA molecule into two 
pieces, yielding 5541 bp and 2283 bp fragments (Figure 24). 
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Figure 24: Restriction assay for regulator C1R5. Wells 1-6 show correct clones. For this 
research, clones # 3 and 4 were used. These clones were of appropriate sizes (2283 and 5541 
respectively). 
Construct pC28R was cut with EcoRI.  After restriction, fragments of 5781 bp and 3024 bp 
should be observed on a gel (Figure 25).  
Figure 25: Restriction assay for pC1R4. Wells 8 and 9 contain the DNA fragments of correct sizes 
(5781 and 3024 respectively). 
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4.4.3 Conjugation of Constructs for Expression of Regulatory Genes into S. 
bambergiensis 
As a totally non-methylating E. coli host is needed as DNA donor for conjugation into 
Streptomyces, constructs containing regulatory genes were transformed into competent E. coli 
ET12567 cells. Cells were incubated on LA plates with   Am100, as the vector has an Am –
resistance marker, and then on plates with Am, Cml and Kan to support both vector with 
regulatory gene and helper plasmid pUZ8002. (Kieser T. , Bibb, Buttner, Chater, & Hopwood, 
2000) 
The vectors were then introduced into S. bambergiensis MoeD strain.  Streptomyces clones, 
which received plasmid during conjugation, were selected by Am50, and Nal30 was used to get 
rid of E. coli cells. 
4.5 UV Scans 
In order to get first indications of novel products, UV scans of butanol extractions of S. 
bambergiensis MoeD C1R4, S. bambergiensis MoeD C1R5, S. bambergiensis MoeD C28R 
were done.  
Strains were fermented for 6 days as described in the methods and UV scans were made using 
butanol extractions from those fermentations. 
For UV scans, the moenomycin deletion mutant, S. bambergiensis MoeD, was used as control. 
No peaks were seen from the butanol extractions of S. bambergiensis MoeD C1R4 and S. 
bambergiensis MoeD C1R5, but a peak was obsereved from the butanol extractions of S. 
bambergiensis MoeD C28R as can be seen in the following figure (Figure 26). 
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Figure 26: An absorbance peak of about 0.19 was observed at about 290 nm. 
4.6 Growth Inhibition Bio Assay 
For growth inhibition bio assay, methanol extracts from the cells of recombinant Streptomyces 
strains were used. 
Growth inhibition can be seen by the formation of clear zones around putative bio active 
substance placed on a lawn of an indicator strain. Methanol extracts were placed on paper disks, 
which were dried and then transferred onto plates containing E. coli (Gram negative), B. subtilis 
(Gram positive) and S. cerevisiae (Eukaryote), respectively. Zone of inhibition was observed 
in LA plates with B. subtilis and paper disks with methanol extraction of S. bambergiensis 
MoeD C28R, fermented in media S800 and 5288. Small activity can be seen on the LA plates 
with B. subtilis and paper disks with methanol extraction of S. bambergiensis MoeD, fermented 
in media 5288 suggesting that the target gene cluster may be weakly expressed in this medium 
(Figure 27). 
No inhibition zones were observed on S. cerevisiae and E. coli plates. 
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Figure 27: Figure showing the LA plates with B. subtilis. Paper disks were inoculated with 
methanol extractions from S. bambergiensis MoeD and S. bambergiensis MoeD C28. Inhibition 
zones formed in methanol extraction of S. bambergiensis MoeD C28 from S800 and 5288 
fermentation media, respectively, indicating antibiotic activity. Some activity is seen in media 
5288 on the plate with the S. bambergiensis MoeD extractions. 
4.7 LC-MS of the Methanol Extracts 
LC-MS was done with the methanol extractions of S. bambergiensis MoeD and S. 
bambergiensis MoeD C28R, from the 5288 fermentation media. S. bambergiensis MoeD was 
used as control. 
As can be seen in the following figure (Figure 28), a clear peak was observed on LC at 3.739 
minutes in the S. bambergiensis MoeD C28R extract, which was absent in the control strain. 
 
 
Figure 28: This figure shows the chromatogram comparison between the control, S. 
bambergiensis MoeD, extraction (left) and S. bambergiensis MoeD C28R extraction (right). A 
clear peak can be seen at the 3.739 minute mark in the C28R extraction. Other smaller peaks. 
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Analysing the peak at the 3.739 minute mark gives a m/z ratio of 1563 for the molecule. This 
can be seen in the following figure (Figure 29). 
 
Figure 29: Analysing the spectra of the peak at the 3.739 mark, shows that the molecule has an 
m/z ratio of 1563. 
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5 Discussion 
5.1 Genome Mining for Interesting Gene Clusters 
The potential of each microorganism can be vast as it becomes apparent that each strain 
possesses a multitude of biosynthetic gene clusters (Figure 4). (Doroghazi & Metcalf, 2013) 
Many of these gene clusters are not expressed under laboratory conditions. Activating these 
cryptic pathways for the biosynthesis of novel SMs is an innovative way to discover novel 
bioactive compounds. There are a number of methods currently employed by scientists in order 
to activate silent gene clusters. Ribosome engineering is one method, where introduction of a 
mutation in the RNA polymerase has led to activation of biosynthetic pathways. (Ochi & 
Hosaka, 2013) Co-cultivation is another exciting method used for inducing production of silent 
metabolites. Cultivating two bacterial strains together mimics in a way conditions encountered 
in nature. This has been shown to be an effective method to discover novel bioactive 
compounds. (Ochi & Hosaka, 2013) In this project, the method of constitutive overexpression 
of putative pathway-specific regulators was chosen as the method for waking up silent gene 
clusters. The incentive for choosing this method was that the whole genome sequence of S. 
bambergiensis was recently obtained and that this bacteria produces only one known SM, the 
antibiotic moenomycin. (Ostash & Walker, 2010) Streptomyces bacteria are historically 
proliferate producers of biologically active SMs and so S. bambergiensis has a potential to 
biosynthesize a number of different SMs. (Bérdy, 2005) 
Genome mining is a term applied to the use of bioinformatics, molecular genetics and natural 
product analytical chemistry in order to access the metabolic product of a gene cluster found in 
the genome of an organism. (Gomez-Escribano & Bibb, 2014) Now, in the age of genomics, 
thousands of gene clusters are becoming available. With the overflow of information, there is a 
need to filter out the gene clusters that are interesting as possible natural products. Using 
software and databanks such as AntiSMASH and NCBI, the task of filtering the interesting 
gene clusters beomes much less laborious, yet even with the aid of such bioinformatic tools, 
there still are many factors to consider when deciding which gene clusters to research further. 
Currently two methods are used for genome mining in microorganisms, heterologous 
expression and homologous expression, which is the method employed in this project. 
Heterologous expression is the cloning of a fragment of the producing organisms genome, 
containing the gene cluster, and expressing it in a suitable host. (Gomez-Escribano & Bibb, 
2014) This can enable characterisation of biosynthetic pathways in a genetically amenable host. 
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(Ongley, Bian, Neilan, & Muller, 2013) There are generally many different rationales for 
choosing to heterologously express certain genes, such as slow growth rate and difficulty in 
laboratory cultivation of original strain, host strain being well characterised and proving to be 
a superior producer to original strain, for instance (Jones, et al., 2012) There are also a number 
of difficulties associated with heterologous expression. The compound produced might be too 
toxic for new host, some additional cofactors and interactions might be missing. Improper post-
translational folding of proteins in heterologous host can be problematic also and as many gene 
clusters are very large, the transfer of genetic material to another host can be very difficult. 
(Ongley, Bian, Neilan, & Muller, 2013)  
Obviously many of these challenges are not an issue during homologous expression. Other 
problems arise instead, such as poorly characterized regulator pathways and regulators may not 
be controlling expression of all necessary genes in the cluster. (Bibb M. J., 2005) 
Homologously overexpressing genes can be done in one of two ways, by over expressing cluster 
specific activators or by inactivating repressors. (Zotchev, Sekurova, & Katz, 2012) In this 
project, the goal was to identify biosynthetic gene clusters of S. bambergiensis for potentially 
novel SMs and activate these gene clusters via overexpression of their pathway-specific 
regulators. After careful in silico mining using the bioinformatics tool AntiSMASH and the 
BLAST feature of the NCBI website, the gene clusters chosen for targeted activation were 
clusters 1 and 28. In both these clusters the regulators in question were activators. 
According to in silico mining using AntiSMASH, gene cluster 1 of S. bambergiensis is a non-
ribosomal peptide synthetase. The fact that many known antibiotics are produced by non-
ribosomal synthetases (Finking & Marahiel, 2004) and low homology to genes in the NCBI 
databank, made this cluster an interesting choice for targeted activation. 
AntiSMASH analysis of gene cluster 28 showed that this cluster was a type I polyketide 
synthase gene cluster. Polyketides are a large class of diverse compounds. Many important 
antibiotics belong to the polyketide class, including macrolides. (Alekhova & Novozhilova, 
2001) The putative polyketide produced by the polyketide synthase in this cluster would be a 
66-membered macrolide, the largest identified to date. The cluster itself spans over 190 kb and 
contains 30 putative biosynthetic genes. 
5.2 Removing Background for the Discovery of Novel Compounds 
For the discovery of novel bioactive compounds, it is necessary to eliminate as much 
background interference as possible. The only known bioactive compound produced in the case 
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of S. bambergiensis is moenomycin. (Ostash & Walker, 2010) Moenomycin is an inhibitor of 
peptidoglycan glycosyltransferases and so it inhibits cell wall biosynthesis. The only explored 
phosphoglycolipid biosynthetic pathway is that of Streptomyces ghanaensis. (Ostash & Walker, 
2010) Genes with high homology to genes identified in S. ghanaensis relating to biosynthesis 
of moenomycin, were found in S. bambergiensis as a result of in silico mining in AntiSMASH 
(See Annex 1). These genes were found in gene cluster 2. Targeted gene inactivation with the 
help of gusA reporter gene is a well established method. (Siegl & Luzhetskyy, 2012) This 
method was used to succesfully delete gene cluster 2 from the S. bambergiensis, resulting in 
the recombinant strain, S. bambergiensis MoeD or moenomycin deletion mutant of S. 
bambergiensis, incapable of moenomycin production. 
5.3 Selecting Regulatory Genes for Overexpression 
In silico mining of S. bambergiensis showed that cluster 28 contains one regulatory gene. 
AntiSMASH analysis showed this to be a LuxR family transcriptional regulator (See Appendix 
2). LuxR regulatory genes are known to be involved in the biosynthesis of antibiotics as 
activators of gene expression, so this was a good candidate for overexpression. (Chen & Xie, 
2011) AntiSMASH analysis of cluster 1 showed that this cluster contains 5 regulatory genes 
(See Appendix 2). Regulatory gene 4 is a putative LuxR family transcriptional regulator and so 
using the same rationale as for gene cluster 28, this was a good candidate for overexpression. 
Regulatory gene 5 is of the SARP family of regulators. SARP family of regulators are known 
activators of biosynthetic genes in gene clusters. (Aigle & Corre, 2012) This made regulatory 
gene 5 in cluster 1 also a good candidate for overexpression. 
5.4 Discovery of a Novel Bioactive Compound 
Once the regulatory constructs were successfully integrated into the recombinant strain, S. 
bambergiensis MoeD, a bioassay was done to check for novel bioactive compounds. Following 
6 days of fermentation, an extraction was done as explained in the methods. These extraction 
were used for the bioassays. The extraction of the 6 day fermentation of S. bambergiensis MoeD 
C28R showed inhibition activity against the Gram + bacteria, B. subtilis. No inhibition was 
shown against the Gram – E. coli or the eukaryotic S. cerevisiae. LC-MS of the extract showed 
a putative molecule with an m/z ratio of 1563.  
5.5 Significance 
Laureti et al discovered a 51-membered macrolide (stambomycin) by waking up a gene cluster 
in S. ambofaciens. This molecule was elucidated and found to have an m/z ratio of 1375. This 
macrolide was shown to have inhibitory activity against Gram + bacteria but no activity against 
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Gram – bacteria. Interestingly this macrolide inhibits proliferation of human adenocarcinoma 
cell lines. (Laureti, et al., 2011) The m/z ratio of the putative compound from this project 
correlates with the predicted 66-membered polyketide and has predicted inhibitory activity of 
a macrolide, that is, shows activity against Gram + bacteria and no activity against Gram – 
bacteria.  
5.6 Way Forward 
The compound discovered in this project has a high commercial potential. The way forward for 
this work would be to purify the compound and elucidate the structure of the molecule. It would 
be very interesting to see if this compound has antiproliferative capabilities against human 
cancer cell lines, as was evident with the macrolide discovered by Laureti et al.  
This project focused on two gene clusters in S. bambergiensis, there are still numerous gene 
clusters unexplored and so this bacteria holds even more potential. In the course of this work 
two additional mutants were successfully integrated with overexpression vectors. Unfortunately 
these were created successfully towards the end of the project so due to time restriction, these 
could not be investigated thoroughly. 
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6 Conclusion 
By waking up a silent gene cluster with the overexpression of regulators within the gene cluster, 
this project led to the successful production of a putative biologically active product.  
The discovery of a 51-membered macrolide by Laureti et al in 2011 led to the identification of 
stambomycins A-D. These have shown moderate activity against Gram positive bacteria, but 
more importantly, they inhibited proliferation of human adenocarcinoma (HT29) cell lines. 
Laureti et al also observed significant antiproliferative activities against the human breast 
(MCF7), lung (H460) and prostate (PC3) cancer cell lines. This would indicate that 
stambomycins might represent promising new leads for anticancer drug discovery. (Laureti, et 
al., 2011) 
There is promising evidence that the S. bambergiensis MoeD C28R strain is producing the 
antiSMASH predicted 66-membered macrolide. Further identification of this molecule and tests 
against human cell lines might prove very interesting.  
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8 Appendices 
8.1 Appendix 1 
Annotations of gene clusters using antiSMASH, Excel and BLAST. Function is based on 
highest hit in BLAST. 
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8.2 Appendix 2 
Annotation of all regulatory genes found in in silico mining of gene clusters in S. 
bambergiensis. 
Cluster Type of Cluster Type of Regulator 
Cluster 1 Nrps   
R1 smCOG1136 GenTr Family Transcriptional Regulator 
R2 smCOG1058 ArsR Family Transcriptional Regulator 
R3 smCOG1016 LuxR Family DNA-Binding Response Regulator 
R4 smCOG1149 LuxR Family Transcriptional Regulator 
R5 smCOG1041 Transcriptional Regulator SARP Family 
Cluster 3 Other   
R1 smCOG1041 Transcriptional Regulator SARP Family 
R2 smCOG1008 Response Regulator 
Cluster 4 Nrps-t1pks   
R1 smCOG1008 Response Regulator 
Cluster 5 Lantipeptide   
R1 smCOG1195 IclR Family Transcriptional Regulator 
R2 smCOG1016 LuxR Family DNA-Binding Response Regulator 
Cluster 7 Type 2 pks   
R1 smCOG1071 GntR Family Transcriptional Regulator 
R2 smCOG1058 ArsR Family Transcriptional Regulator 
R3 smCOG1078 LacI Family Transcriptional Regulator 
R4 smCOG1135 MarR Family Transcriptional Regulator 
R5 smCOG1260 AraC Family Transcriptional Regulator 
R6 smCOG1030 Serine / Threonine Protein Kinase 
Cluster 9 Type 1 pks   
R1 smCOG1041 Transcriptional Regulator SARP Family 
Cluster 12 Nrps-type 1 pks   
R1 smCOG1136 GenTr Family Transcriptional Regulator 
Cluster 14 Type 1 pks   
R1 smCOG1078 LacI Family Transcriptional Regulator 
Cluster 19 Type 3 pks   
R1 smCOG1041 Transcriptional Regulator SARP Family 
R2 smCOG1135 MarR Family Transcriptional Regulator 
R3 smCOG1041 Transcriptional Regulator SARP Family 
R4 smCOG1284 Transcriptional Regulator MarR Family 
R5 smCOG1041 Transcriptional Regulator SARP Family 
R6 smCOG1041 Transcriptional Regulator SARP Family 
R7 smCOG1014 LysR Family Transcriptional Regulator 
R8 smCOG1195 IclR Family Transcriptional Regulator 
Cluster 20 Nrps-type 1 pks   
R1 smCOG1197 Autoinducer - Binding Transcriptional Regulator 
Cluster 22 Nrps   
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Cluster Type of Cluster Type of Regulator 
R1 smCOG1078 LacI Family Transcriptional Regulator 
Cluster 24 Bacteriocin - t1pks   
R1 smCOG1078 LacI Family Transcriptional Regulator 
Cluster 25 Nrps   
R1 smCOG1078 LacI Family Transcriptional Regulator 
R2 smCOG1016 LuxR Family DNA-Binding Response Regulator 
R3 smCOG1016 LuxR Family DNA-Binding Response Regulator 
Cluster 27 Nrps-type 1 pks   
R1 smCOG1041 Transcriptional Regulator SARP Family 
R2 smCOG1041 Transcriptional Regulator SARP Family 
Cluster 28 Type 1 pks   
R1 smCOG1149 LuxR Family Transcriptional Regulator 
Cluster 29 
Nrps-bacteriocin-
terpene   
R1 smCOG1016 LuxR Family DNA-Binding Response Regulator 
 
